AstraZeneca Investor Day Presentation Deck slide image

AstraZeneca Investor Day Presentation Deck

Most common adverse events AE profile was consistent with the known toxicity profiles for the individual drugs Any 97.2 Anemia* Fatigue or asthenia Nausea Diarrhea Constipation Back pain Decreased appetite Vomiting Arthralgia Hypertension Dizziness Peripheral edema Urinary tract infection 100 80 Olaparib + abiraterone (n=399) Placebo + abiraterone (n=399) 47.2 38.4 46.0 60 37.2 28.1 40 15.1 17.3 17.3 17.1 14.6 13.1 0.8 1.0 1.0 2.3 1.5 0.3 0.3 12.6 0.8 0.3 9.3 12.8 12.6 3.5 10.8 10.3 10.3 2.0 20 3.3 0.3 00 1.0 3.3 16.4 6.3 13.9 5.8 0.3 9.1 0.5 17.7 16.4 0.3 11.4 1.0 7.8 18.4 20 28.3 40 60 80 94.9 100 Safety was assessed through the reporting of AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.03) and laboratory assessments. 19 *Anemia category includes anemia, decreased hemoglobin level, decreased red-cell count, decreased hematocrit level, erythropenia, macrocytic anemia, normochromic anemia,normochromic normocytic anemia, and normocytic anemia. Grade 23 All grade Grade 23 All grade 3
View entire presentation